This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q77.1 (thanatophoric dysplasia) | Special Copayment Reduction: V228 (ultra-rare disease) |
| B. Synonyms | Thanatophoric dwarfism, Thanatophoric dysplasia, Thanatophoric dysplasia type I (TD-I), Thanatophoric dysplasia type II (TD-II), FGFR3-related lethal skeletal dysplasia |
| C. Adult onset | Possible first onset in adulthood: very low — thanatophoric dysplasia is a perinatal lethal disease in which death occurs almost universally in the neonatal period. Fewer than a few dozen long-term survivors have been reported worldwide, and even these are accompanied by severe neurological impairment and respiratory dependence. |
| 1. History | 1967 first description and naming by Maroteaux, Lamy, and Robert → 1992 classification into TD-I and TD-II → 1994 identification of the FGFR3 gene → 1995 identification of the K650E (TD-II) and R248C, Y373C (TD-I) variants → continued functional studies of FGFR3 variants thereafter. |
| 2. Causes | De novo gain-of-function variants of the FGFR3 gene (4p16.3). TD-I: various missense variants such as R248C, Y373C, S249C. TD-II: K650E variant in more than 90%. FGFR3 overactivation → abnormal RAS-MAPK and STAT pathways → suppression of growth plate chondrocyte proliferation. |
| 3. Genetics | Autosomal dominant, almost all de novo variants. FGFR3 gene (4p16.3), 19 exons. Recurrence risk below 1% (germline mosaicism possible). Associated with advanced paternal age. Same gene as the achondroplasia-hypochondroplasia spectrum. |
| 4. General epidemiology | 1 in 20,000~50,000 births. The most common lethal skeletal dysplasia. TD-I is about twice as frequent as TD-II. Unrelated to sex or ethnicity. Registrations in Korea are very few under special copayment reduction code V228. |
| 5. Pathophysiology | FGFR3 overactivation → sustained activation of the STAT1, STAT3, and MAPK pathways → upregulation of p21 (CDKN1A) → G1 arrest of growth plate chondrocytes → suppression of cell proliferation and hypertrophy → arrest of endochondral ossification. In addition, abnormal FGF23 signaling pathways cause premature closure of the skull sutures (craniosynostosis). |
| 6. Symptoms | Extreme limb shortening (proximal > distal), short narrow thorax, pulmonary hypoplasia, large head. TD-I: curved (phone receiver) femur. TD-II: straight femur + cloverleaf skull (kleeblattschädel). Respiratory failure immediately after birth. |
| 7. Signs | X-ray: short, curved (TD-I)/straight (TD-II) femur, flattened vertebral bodies (platyspondyly), short ribs, typical H-shaped vertebrae. Skull: premature closure of the cranial sutures, skull base narrowing (severe in TD-II). Excess skin folds. Polyhydramnios. |
| 8. Screening | Detailed prenatal ultrasound at 14~22 weeks of gestation: extreme limb shortening (abnormal FL/AC ratio), narrow thorax, head overgrowth. 3D ultrasound to confirm skull shape (cloverleaf in TD-II). FGFR3 variant analysis on amniotic fluid or chorionic villus DNA (confirmation). |
| 9. Diagnosis | Prenatal ultrasound (main screening) + fetal/neonatal DNA FGFR3 variant analysis (confirmation). Whole-body skeletal radiographs (babygram). Fetal MRI (assessment of skull shape and brain structure). Pathology: loss of the hypertrophic chondrocyte zone of the growth plate. Postmortem autopsy is standard. |
| 10. Treatment | No curative treatment. Perinatal palliative care. Rare long-term survivors: dependence on mechanical ventilation; tracheostomy, ventriculoperitoneal shunt for hydrocephalus, and cranial suture release are considered. Experimental treatments such as C-type natriuretic peptide (CNP) analogs are under investigation. |
| 11. Prognosis | Almost universal neonatal death (within minutes to hours). In rare long-term survivors, severe intellectual disability, seizures, dependence on mechanical ventilation, and recurrent respiratory infections. Recurrence risk 1~2% (germline mosaicism). Genetic counseling is essential. |
| 12. Prevention | Genetic counseling and recurrence risk assessment. After confirming the FGFR3 variant in a previously affected child, prenatal genetic testing in the next pregnancy (CVS/amniocentesis). Enhanced detailed prenatal ultrasound. Advance formation of a perinatal palliative care team. |
| 13. References | Maroteaux P et al. 1967 Presse Med; Rousseau F et al. 1994 Nature; Tavormina PL et al. 1995 Nature Genet … and 7 others |
Thanatophoric dysplasia was first named in 1967 when the French physicians Pierre Maroteaux, Maurice Lamy, and Robert described two newborns who died of extreme short stature and respiratory failure. The name 'thanatophoric' derives from the Greek 'thanatos (θάνατος, death)' and 'phoros (φόρος, bearing)', literally expressing a disease that 'brings death'. This clinically reflects that the disease is the most common lethal neonatal skeletal dysplasia.
After the original description by Maroteaux et al., similar cases were reported around the world and the clinical spectrum expanded. In 1973, Lainer and Rimoin suggested the possibility of two subtypes based on differences in skull shape, and in 1992 Lanoue and colleagues formally classified them into type I (TD-I: curved femur, cloverleaf skull absent or rare) and type II (TD-II: straight femur, cloverleaf skull required). This classification is based on the radiographic phenotype and remains the clinical standard to this day.
Understanding at the molecular level advanced rapidly in 1994 when the association of the FGFR3 (fibroblast growth factor receptor 3) gene with achondroplasia was identified. In 1994, Rousseau et al. identified the FGFR3 gene as the causative gene of achondroplasia, and in 1995 Tavormina et al. and Shiang et al. each showed that gain-of-function mutations of FGFR3 are present in thanatophoric dysplasia in a much more potent form. In particular, the K650E variant within the tyrosine kinase domain of FGFR3 was identified in TD-II, and variants at multiple positions such as R248C, Y373C, and S249C in TD-I.
Since then, molecular and cell-biological research on the FGFR3 signaling pathway has intensified, and the mechanism by which growth plate chondrocyte proliferation is suppressed through the STAT1, STAT3, and MAPK (ERK1/2) pathways has been elucidated. These studies showed that achondroplasia and thanatophoric dysplasia lie at opposite ends of the phenotypic spectrum of FGFR3 overactivation, and on this basis research was carried out on developing therapeutics using FGFR3 inhibitors and C-type natriuretic peptide (CNP) analogs. The CNP analog vosoritide, for achondroplasia, was approved by the FDA in 2021, setting a new milestone in research on treatments for skeletal dysplasias, and a similar approach is being explored for thanatophoric dysplasia.
In Korea, thanatophoric dysplasia is a perinatal lethal disease classified under special copayment reduction code V228, and NGS-based prenatal diagnosis and a multidisciplinary approach to perinatal palliative care are developing in the direction of standardization.
The cause of thanatophoric dysplasia is a pathogenic variant of the FGFR3 (fibroblast growth factor receptor 3) gene located on the short arm of chromosome 4 (4p16.3). FGFR3 is a transmembrane receptor tyrosine kinase that is highly expressed in limb cartilage, growth plate chondrocytes, and the brain, and acts as a key regulator controlling the rate of endochondral ossification.
Under normal conditions, FGFR3 is transiently activated after binding to FGF ligands, which appropriately suppresses growth plate chondrocyte proliferation and controls the rate of skeletal growth. In thanatophoric dysplasia, FGFR3 variants show a gain-of-function effect in which the receptor is continuously activated even without ligand-dependent activation, so growth plate chondrocyte proliferation is severely suppressed.
Variants in type I (TD-I): FGFR3 variants at various positions have been reported. The most common variants are R248C (CGC→TGC) and Y373C (TAC→TGC); most of these cause abnormal disulfide bond formation in the extracellular or transmembrane domain of the receptor, leading to receptor dimerization and sustained activation without ligand. Variants such as S249C and R248H are also reported. In TD-I, the genotype-phenotype correlation is incomplete, so skull shape may differ even with the same variant.
Variants in type II (TD-II): in more than 90% of TD-II, the K650E (AAA→GAA) variant in FGFR3 exon 15 is identified. K650 is a key residue of the activation loop of the FGFR3 tyrosine kinase, and the K650E variant structurally locks the tyrosine kinase domain in a permanently active state. K650E causes much stronger FGFR3 overactivation than the TD-I variants, which explains why premature closure of the cranial sutures (craniosynostosis) and cloverleaf skull (kleeblattschädel) are more frequent and more severe in TD-II.
Almost all thanatophoric dysplasia variants are de novo (newly arising spontaneous) variants, and the parents' FGFR3 genes are normal. An advanced paternal age effect has been reported, and the older the father, the higher the frequency of de novo variants is known to be. This is because the more times sperm cells divide, the greater the probability of replication errors.
Thanatophoric dysplasia follows an autosomal dominant mode of inheritance, and clinically almost all cases occur as de novo mutations. Because patients mostly die in the perinatal period, transmission of the variant to offspring is extremely rare.
Structure of the FGFR3 gene: FGFR3 is located on the short arm of chromosome 4 (4p16.3), with a total size of about 16.5 kb and 19 exons. The FGFR3 protein consists of an extracellular ligand-binding domain containing three immunoglobulin-like (Ig-like) domains, a single transmembrane domain, and a split intracellular tyrosine kinase domain. The ligand-binding domain has two splice variants, IIIb and IIIc, and the IIIc form is predominantly expressed in cartilage.
FGFR3 disorder spectrum: various variants of the FGFR3 gene cover a broad spectrum of skeletal phenotypes according to severity. In order from severe to mild: thanatophoric dysplasia type II (K650E) > thanatophoric dysplasia type I (R248C, Y373C, etc.) > SADDAN (K650M, severe achondroplasia with developmental delay and acanthosis nigricans) > achondroplasia (G380R) > hypochondroplasia (N540K, etc.). This spectrum shows that the stronger the FGFR3 overactivation, the more severe the phenotype.
Germline mosaicism: although this is a disease caused by de novo variants, a small number of cases have been reported in which a second affected child was born to the same parents. This is due to germline mosaicism, in which the FGFR3 variant is present in some germ cells of a parent (mainly the father). Therefore, the recurrence risk is theoretically below 1% but not completely zero, and when there is a previously affected child, offering prenatal diagnosis in the next pregnancy is standard.
Advanced paternal age effect: the occurrence of de novo variants in the FGFR3 gene is related to the father's age. Male spermatogonial stem cells divide continuously, so the number of divisions increases with age and the risk of replication errors rises. This is called the 'advanced paternal age effect', and in a considerable proportion of thanatophoric dysplasia the father's age is statistically higher. However, because it also occurs in young parents, this is not an absolute risk factor.
Molecular diagnostic strategy: when TD-I is suspected on prenatal diagnosis, frequent variants such as FGFR3 exons 9 and 10 (R248C, S249C) and exon 13 (Y373C) are analyzed first, and for TD-II, exon 15 (K650E) is analyzed in a targeted manner. If the frequent variants are negative, analysis is extended to all FGFR3 exons (Sanger or NGS) or a skeletal dysplasia panel.
Thanatophoric dysplasia is the most common lethal neonatal skeletal dysplasia and is reported to occur in 1 in 20,000~50,000 births worldwide. Estimates of birth frequency differ by source, mainly because many cases are not included in live-birth statistics owing to intrauterine death or prenatal termination of pregnancy.
Frequency by subtype: TD-I is reported about 2~3 times more often than TD-II. In TD-I, the R248C and Y373C variants are frequent variants, each accounting for about 30~35% of all TD-I cases. In TD-II, the K650E variant accounts for more than 90%. Cloverleaf skull (kleeblattschädel, trilobar skull) is observed in about 10~30% of TD-I and in almost all cases of TD-II.
Sex and ethnicity: thanatophoric dysplasia occurs with equal frequency in males and females, and there is no evidence of higher incidence in a particular ethnic group or region. It occurs sporadically in all populations worldwide. Because of the association with the advanced paternal age effect, the frequency may be somewhat higher with older fathers (35 years or older).
Status in Korea: in Korea, it is registered under the ultra-rare disease special copayment reduction (V228) and medical expense support is available, but because of its nature as a perinatal lethal disease, the number of registered patients is extremely small. With advances in domestic prenatal ultrasound technology and wider availability of NGS-based prenatal genetic testing, the possibility of diagnosis at 14~22 weeks of gestation is increasing. The importance of a multidisciplinary perinatal palliative care approach after prenatal diagnosis is being emphasized in the field of perinatal medicine in Korea.
Epidemiological particularity: thanatophoric dysplasia forms the FGFR3 disorder spectrum together with achondroplasia, but unlike achondroplasia (1 in 25,000 births, survivable), thanatophoric dysplasia is a disease for which life cannot be saved with current medical technology. This creates a fundamental difference in the epidemiological and clinical management of the two diseases. When a lethal skeletal dysplasia is suspected on prenatal ultrasound, the patient should be referred as promptly as possible to a perinatal medicine specialty center so that detailed evaluation and comprehensive family support can be provided.
The pathophysiology of thanatophoric dysplasia is explained by a cascade of pathological overactivation of FGFR3 and the resulting suppression of growth plate chondrocyte proliferation and differentiation. In normal skeletal development, FGFR3 binds ligands such as FGF18 in the growth plate, is transiently and reversibly activated, and acts as a negative regulator that appropriately controls chondrocyte proliferation.
Mechanism of FGFR3 overactivation: extracellular domain variants such as R248C and Y373C in TD-I form abnormal intermolecular disulfide bonds, so FGFR3 dimers form without ligand and constitutive activation is maintained. The K650E variant in TD-II locks the tyrosine kinase activation loop in a permanently open (active conformation) structure, so kinase activity persists regardless of ligand. The degree of kinase overactivation by the K650E variant is much stronger than that of the TD-I variants, which explains the severity of the TD-II phenotype.
STAT pathway activation: overactivated FGFR3 phosphorylates and activates STAT1 through Janus kinase (JAK), and STAT1, as a transcription factor, upregulates p21 (CDKN1A). p21 is a cell cycle inhibitor that induces G1 cell cycle arrest in growth plate proliferating chondrocytes, blocking chondrocyte proliferation. This effect is much stronger in TD-II than in TD-I, so growth plate function is completely paralyzed.
MAPK/ERK pathway activation: FGFR3 overactivation also activates the Grb2-SOS-RAS-RAF-MEK-ERK1/2 pathway, which further suppresses chondrocyte differentiation and hypertrophy. In particular, suppression of Runx2 (an osteoblast differentiation factor) by ERK1/2 interferes with the conversion of cartilage to bone and impairs the bone turnover of chondrocytes in the growth plate hypertrophic zone.
Mechanism of premature cranial suture closure: because FGFR3 is also expressed in meningeal cells and osteoblasts at the cranial sutures, FGFR3 overactivation causes premature suture closure (craniosynostosis). In TD-II, premature cranial suture closure is more severe and forms a cloverleaf skull (kleeblattschädel), which causes increased intracranial pressure, hydrocephalus, and brainstem compression, further worsening the neurological prognosis. In addition, narrowing of the skull base and foramen magnum compresses the cervical spinal cord and causes central apnea.
The clinical symptoms of thanatophoric dysplasia are already prominent in the fetal period before birth, and immediate respiratory failure after birth is the key life-threatening symptom. TD-I and TD-II each show common symptoms and subtype-specific findings.
Common symptoms — limb shortening: extreme shortening (micromelia) is observed in all limbs, and rhizomelia, in which shortening of the proximal segments (arm, thigh) is greater than that of the distal segments (forearm, lower leg), is prominent. The limbs appear short and fleshy, with excessive skin folds.
Common symptoms — narrow thorax and respiratory failure: the thorax is extremely narrow and short, and the resulting pulmonary hypoplasia is the cause of immediate respiratory failure after birth. Spontaneous breathing is impossible or extremely insufficient, and even when endotracheal intubation and mechanical ventilation are attempted, sufficient oxygenation is not achieved because of impaired alveolar development.
TD-I-specific symptoms: the most characteristic finding is a curved (bowed) femur, which looks like a telephone receiver on X-ray. Premature cranial suture closure may be relatively mild or absent, and cloverleaf skull is observed in only about 10~30% of TD-I cases. The forehead is markedly prominent and the nasal root is flat. The vertebrae are flattened (platyspondyly), with the lateral width markedly greater than the vertical height.
TD-II-specific symptoms: the femur is relatively close to straight. Premature cranial suture closure (craniosynostosis) is severe, and a cloverleaf skull (kleeblattschädel, trilobular skull) forms in almost all cases; because of premature closure of the cranial sutures, brain growth expands only toward the anterior fontanelle and the temporo-parietal regions, producing a cloverleaf-shaped skull. Increased intracranial pressure causes hydrocephalus, brainstem compression, and cervical spinal cord compression. Upper airway narrowing accompanies skull base narrowing, making airway securing even more difficult.
Prenatal fetal findings: polyhydramnios, limb shortening (identified on ultrasound from 14~16 weeks of gestation), head overgrowth, and a narrow thorax are the main fetal findings. Fetal hydrops accompanies some cases, and in TD-II the cloverleaf skull shape is often identified on ultrasound in the late second to early third trimester.
The clinical signs of thanatophoric dysplasia appear characteristically on prenatal ultrasound, physical examination, radiographic imaging, and pathological examination, respectively.
Prenatal ultrasound signs: femur length (FL) is reduced to -4 SD or below for gestational age, and the chest circumference/abdominal circumference ratio is markedly low. Head circumference (HC) is large or normal relative to gestational age. In TD-II, the skull shape is seen as a cloverleaf, which is confirmed more clearly by 3D ultrasound. Polyhydramnios (AFI > 25 cm) frequently accompanies it.
Neonatal physical examination signs: immediate cyanosis and respiratory distress after birth. The thorax is extremely narrow and the abdomen is relatively protuberant. The limbs are short with many skin folds. The head is large, and the cloverleaf shape is clear in TD-II. Frontal bossing, increased interocular distance (ocular hypertelorism), and a flat midface. Cleft palate accompanies some cases. Body weight is within the normal range or slightly low.
Skeletal radiographic signs: main findings on whole-body skeletal radiographs (babygram): ① short, curved femur (TD-I, telephone receiver type) or short, straight femur (TD-II). ② Platyspondyly: flattened vertebral bodies that are wide laterally, showing an H shape or inverted U shape. ③ Short ribs with horizontal alignment. ④ Horizontal acetabular roof of the pelvis and underdeveloped ischial tuberosities. ⑤ Findings of premature cranial suture closure (TD-II).
Pathological and histological signs: in growth plate tissue, marked reduction or loss of the proliferating chondrocyte zone is observed. The hypertrophic chondrocyte zone is also abnormally disorganized and short. The cartilage matrix is poorly mineralized, and primary spongiosa is not formed or is extremely limited. In brain tissue, heterotopic neurons, cortical dysplasia, and hippocampal abnormalities are observed in some cases.
Laboratory findings: in neonates, hypoxemia and hypercapnia occur and acidemia progresses rapidly. There are no other specific laboratory findings. Molecular diagnosis (FGFR3 variant analysis) is essential for definitive diagnosis.
There is no general population screening program for thanatophoric dysplasia, and prenatal ultrasound is the most important screening tool. In Korea, prenatal ultrasound covered by National Health Insurance is standardized, so abnormal findings can be detected on detailed ultrasound at 18~22 weeks of gestation.
Detailed prenatal ultrasound: femur shortening begins to be observed from 14~16 weeks of gestation, and on detailed ultrasound at 18~22 weeks, extreme shortening of femur length (FL) (-4 SD or below), narrow chest circumference, and head overgrowth become distinct. Confirming femoral curvature (TD-I) and skull shape (cloverleaf in TD-II) is key. Amniotic fluid index (AFI) measurement and evaluation of overall fetal structure (heart, kidneys, brain, abdominal organs) are performed together.
3D/4D ultrasound and MRI: 3D ultrasound is useful for three-dimensionally confirming the cloverleaf skull shape of TD-II and for quantitatively evaluating fetal thoracic volume. Fetal MRI evaluates brain structural abnormalities (cortical dysplasia, hydrocephalus, heterotopic neurons), lung volume (lung/liver signal ratio), and the degree of cranial suture closure, compensating for the resolution limits of ultrasound.
Biochemical screening tests: prenatal screening tests based on serum markers (AFP, HCG, uE3, inhibin A) are not specific for skeletal dysplasia and are not used for screening thanatophoric dysplasia. Cell-free fetal DNA analysis based on NIPT is also not currently applied as standard clinical practice.
Molecular screening of high-risk groups: when thanatophoric dysplasia was confirmed in a previous pregnancy (FGFR3 variant identified), prenatal confirmation is possible in the next pregnancy by targeted FGFR3 variant analysis after chorionic villus sampling (CVS, 11~14 weeks) or amniocentesis (15~20 weeks). Because of the possibility of germline mosaicism, the recurrence risk is not completely zero, so prenatal diagnosis is always recommended when there is a previously affected child.
Definitive diagnosis of thanatophoric dysplasia is made by integrating prenatal ultrasound findings, whole-body skeletal radiographs, molecular genetic FGFR3 variant analysis, and pathological examination.
Prenatal ultrasound diagnosis: on detailed ultrasound at 14~22 weeks of gestation, extreme femur shortening, narrow chest circumference, and head overgrowth are confirmed, and the subtype is distinguished by femoral curvature (TD-I) or cloverleaf skull (TD-II). Ultrasound findings alone require differentiation from achondrogenesis, campomelic dysplasia, and others, and the final diagnosis is confirmed by molecular diagnosis.
Molecular genetic diagnosis: DNA is extracted from fetal tissue (chorionic villi, amniotic cells) or postmortem tissue, and the frequent FGFR3 variants (R248C, Y373C — TD-I; K650E — TD-II) are analyzed in a targeted manner. If the frequent variants are negative, analysis is extended to all FGFR3 exons or a skeletal dysplasia panel NGS. After molecular confirmation, the TD-I/TD-II subtype classification is finalized.
Whole-body skeletal radiographs (Babygram): whole-body radiography after birth or postmortem is essential for comprehensively evaluating platyspondyly, short ribs, femur shape (curved vs. straight), and pelvic findings. The final diagnosis is established by integrating radiographic findings with molecular diagnosis.
Pathology and autopsy: at autopsy, lung volume (lung/body weight ratio), growth plate tissue (H&E, immunohistochemistry), cranial suture status, and brain structural abnormalities are evaluated. Tissue blocks and DNA are preserved for use in future molecular testing.
Differential diagnosis: ① Achondrogenesis (Q77.0): lack of vertebral ossification, COL2A1/SLC26A2 variants. ② Campomelic dysplasia: bowing of the lower limbs + SOX9 variant, sex reversal possible. ③ SADDAN: FGFR3 K650M variant, accompanied by acanthosis nigricans, rare survival possible. ④ Short-rib polydactyly syndrome: accompanied by polydactyly. Each disease is distinguished by characteristic radiographic and molecular findings.
There is currently no curative treatment for thanatophoric dysplasia. The focus of medical response is perinatal palliative care, family support, and multidisciplinary management in rare long-term survivors.
Perinatal palliative care: after prenatal diagnosis, a multidisciplinary perinatal palliative care team is formed to provide sufficient information to the pregnant woman and family and support decision-making. Advance plans regarding the mode of delivery (vaginal delivery or cesarean section), whether to perform neonatal resuscitation (endotracheal intubation and mechanical ventilation), and the palliative care approach are made together with the family. Time with the baby after birth is ensured as much as possible, and palliative medication (morphine, etc.) is given to minimize pain.
Active treatment in rare long-term survivors: there are extremely rare cases of long-term survival (months to years) reported in the worldwide literature. They commonly have serious complications such as prolonged mechanical ventilation (including tracheostomy), severe intellectual disability, seizures, and recurrent respiratory infections. In such cases: ① airway management (tracheostomy, mechanical ventilation); ② hydrocephalus treatment (ventriculoperitoneal shunt, VP shunt); ③ treatment of premature cranial suture closure (cranial suture release, craniosynostosis release); ④ cervical spinal cord decompression (foramen magnum decompression); ⑤ seizure treatment (anticonvulsants); ⑥ nutritional support (nasogastric or gastrostomy feeding); ⑦ physical and occupational therapy, etc. are provided in a multidisciplinary manner.
Experimental and investigational treatments: research on therapeutics aimed at improving skeletal growth through FGFR3 inhibition is ongoing. The C-type natriuretic peptide (CNP) analog vosoritide was approved by the FDA in 2021 for achondroplasia, but its effect in thanatophoric dysplasia is not currently established because the degree of FGFR3 overactivation is much more severe. Animal model studies of tyrosine kinase inhibitors, mTOR inhibitors, and others are ongoing.
The prognosis of thanatophoric dysplasia is extremely poor. As the name itself expresses 'bringing death', neonatal death is almost universal in this disease.
Time and cause of death: most patients die of respiratory failure within minutes to hours immediately after birth. Even when endotracheal intubation and mechanical ventilation are attempted, sufficient oxygenation is not achieved because of pulmonary hypoplasia from the narrow thorax and restrictive chest mechanics, and death ultimately results. In TD-II, increased intracranial pressure, brainstem compression, and cervical spinal cord compression from premature cranial suture closure become additional fatal factors.
Rare long-term survival cases: dozens of long-term survival cases have been reported in the worldwide literature. They are accompanied by serious complications such as prolonged dependence on mechanical ventilation, severe intellectual disability, recurrent respiratory infections, and seizures, and quality of life is very limited. This is an area requiring value-based discussion between the family and the medical team about whether to support long-term survival.
Recurrence risk: because it arises from de novo variants, the recurrence risk is theoretically below 1%. However, because cases of recurrence in the same parents due to germline mosaicism have been reported, prenatal diagnosis should always be recommended in the next pregnancy when there is a previously affected child.
Family support and psychological prognosis: families who receive a diagnosis of perinatal lethal disease experience extreme psychological distress. Multidisciplinary psychological support is essential throughout the entire process of prenatal diagnosis, delivery, and neonatal death. In particular, providing sufficient information and non-directive counseling is important in the decision-making process (whether to attempt resuscitation, whether to continue the pregnancy).
Because thanatophoric dysplasia arises as a de novo variant in almost all cases, primary prevention based on family history is limited. However, a systematic prevention strategy can be applied when there is a previously affected child (possible germline mosaicism) and when molecular confirmation has been made.
Genetic counseling: when thanatophoric dysplasia is diagnosed, counseling with a medical geneticist or genetic counselor is essential. Guidance is given on the recurrence risk (1~2%), the possibility of germline mosaicism, and options in the next pregnancy (natural conception + prenatal genetic testing; PGT not possible — embryo selection is difficult owing to the de novo nature). The father's age and the advanced paternal age effect are also explained.
Importance of identifying the variant in a previously affected child: the FGFR3 variant in the previously affected child must be molecularly confirmed and recorded to enable prenatal genetic testing in the next pregnancy. If the variant is not identified, one has no choice but to rely on prenatal ultrasound, and early diagnosis may be delayed. Preservation of postmortem tissue (FFPE blocks) and DNA extraction and analysis are very important.
Enhanced prenatal ultrasound: when there is a previously affected child, periodic detailed ultrasound (every 2~4 weeks) is performed from 12 weeks of gestation in the next pregnancy to detect limb shortening early. If abnormal prenatal ultrasound findings are found, the patient is immediately referred to a perinatal medicine specialty center.
Advance formation of a perinatal palliative care team: after prenatal diagnosis, a team composed of a perinatologist, neonatal intensive care specialist, palliative care specialist, social worker, and psychologist is formed in advance at the delivery hospital to provide integrated perinatal palliative care. This helps minimize the family's shock and confusion and to spend the last time with the baby with dignity.
Maroteaux P, Lamy M, Robert JM. Le nanisme thanatophore. Presse Med. 1967;75(49):2519-2524. PMID: 6057514.
Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994;371(6494):252-254. DOI: 10.1038/371252a0. PMID: 8078586.
Tavormina PL, Shiang R, Thompson LM, et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet. 1995;9(3):321-328. DOI: 10.1038/ng0395-321. PMID: 7773297.
Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev. 2000;21(1):23-39. DOI: 10.1210/edrv.21.1.0393. PMID: 10696568.
Nikkel SM, Major N, King WJ. Thanatophoric dysplasia-survival beyond the neonatal period. J Pediatr. 2011;158(4):678-682. DOI: 10.1016/j.jpeds.2010.09.049. PMID: 21074795.
Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Dev Dyn. 2017;246(4):291-309. DOI: 10.1002/dvdy.24479. PMID: 27987249.
Krakow D, Rimoin DL. The skeletal dysplasias. Genet Med. 2010;12(6):327-341. DOI: 10.1097/GIM.0b013e3181de8a9d. PMID: 20467317.
Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370(9582):162-172. DOI: 10.1016/S0140-6736(07)61090-3. PMID: 17630042.
Unger S, Ferreira CR, Mortier GR, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164-1209. DOI: 10.1002/ajmg.a.63132. PMID: 36779427.
Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. DOI: 10.1002/ajmg.a.61366. PMID: 31633310.